
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL Inc. has experienced a substantial share price increase of nearly 90% over the past month, indicating strong market interest and confidence in the company’s prospects. Recent data from the PATHFINDER 2 ESMO trial has enhanced optimism regarding the upcoming NHS Galleri trial results, while proprietary total addressable market (TAM) analysis suggests significant growth potential in the US and UK, estimated at approximately $3.7 billion by 2026 and $4.0 billion by 2035. Additionally, the establishment of strategic partnerships to tap into this market opportunity further solidifies GRAIL's competitive advantage in the multi-cancer early detection space, despite ongoing uncertainties surrounding regulatory approvals and reimbursement issues.
Bears say
GRAIL Inc has faced substantial net losses since its inception and expects these losses to persist as it continues with clinical studies and seeks regulatory approvals, highlighting a significant financial risk. The company faces numerous challenges, including potential delays in reimbursement pathways for its multi-cancer early detection (MCED) tests and heightened competition from established diagnostic firms, which could hinder its market penetration. Additionally, increased selling, general, and administrative (SG&A) expenses could further strain GRAIL's financial resources, particularly if the company's efforts to expand commercialization of its Galleri test do not yield the expected results.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares